Logo
x

Search category

Subscribe Now

Viatris

Viatris and Sandoz Report Results of Hulio and Hyrimoz (biosimilar, adalimumab) for the Treatment of Inflammatory Bowel Disease

Viatris and Sandoz Report Results of Hulio and Hyrimoz (biosimilar, adalimumab) for the Treatment of Inflammatory Bowel Disease

  • August 11, 2022
Viatris and Biocon Launched Abevmy (biosimilar, bevacizumab) for the Treatment of Cancer in Canada

Viatris and Biocon Launched Abevmy (biosimilar, bevacizumab) for the Treatment of Cancer in Canada

  • May 19, 2022
Insights+ Key Biosimilars Events of March 2022

Insights+ Key Biosimilars Events of March 2022

  • April 7, 2022
Viatris and Biocon’s MYL-1402O (biosimilar, bevacizumab) Demonstrate High Similarity to Avastin in NSCLC

Viatris and Biocon’s MYL-1402O (biosimilar, bevacizumab) Demonstrate High Similarity to Avastin in NSCLC

  • January 3, 2022
Viatris and Biocon’s MYL-1402O (biosimilar, bevacizumab) Demonstrate High Similarity to Avastin in NSCLC

Viatris and Biocon’s MYL-1402O (biosimilar, bevacizumab) Demonstrate High Similarity to Avastin in NSCLC

  • January 3, 2022
PharmaShots Weekly Snapshots (November 15 - 19, 2021)

PharmaShots Weekly Snapshots (November 15 - 19, 2021)

  • November 19, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.